ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat

EMBO Molecular Medicine

Volumn 7, Issue 6, 2015, Pages 831-847

  Meidhof, Simone ^a,b,c   Brabletz, Simone ^c   Lehmann, Waltraut ^a,b   Preca, Bogdan Tiberius ^a,b   Mock, Kerstin ^a,b   Ruh, Manuel ^c   Schüler, Julia ^d   Berthold, Maria ^a   Weber, Anika ^a   Burk, Ulrike ^a   Lübbert, Michael ^a,e   Puhr, Martin ^f   Culig, Zoran ^f   Wellner, Ulrich ^g   Keck, Tobias ^g   Bronsert, Peter ^a   Küsters, Simon ^a   Hopt, Ulrich T ^a   Stemmler, Marc P ^c   Brabletz, Thomas ^c,e  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d CHARLES RIVER LABORATORIES   (United States)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Cancer stem cells; Drug resistance; HDAC inhibitor; MiR 203; ZEB1

Indexed keywords

GEMCITABINE; MICRORNA; MICRORNA 203; MOCETINOSTAT; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; HOMEODOMAIN PROTEIN; MIRN203 MICRORNA, HUMAN; PYRIMIDINE DERIVATIVE; TRANSCRIPTION FACTOR; ZEB1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; DNA MODIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; BIOSYNTHESIS; DRUG EFFECTS; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL LINE, TUMOR; DRUG RESISTANCE; EPITHELIAL-MESENCHYMAL TRANSITION; HISTONE DEACETYLASE INHIBITORS; HOMEODOMAIN PROTEINS; HUMANS; MICRORNAS; PYRIMIDINES; TRANSCRIPTION FACTORS; ZINC FINGER E-BOX-BINDING HOMEOBOX 1;

EID: 84930181902     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201404396     Document Type: Article

References (58)

1. Aghdassi A, Sendler M, Guenther A, Mayerle J, Behn C-O, Heidecke C-D, Friess H, Büchler M, Evert M, Lerch MM et al (2012) Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut 61: 439-448
2. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ, Choi W (2009) Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 69: 5820-5828
3. Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome â€" biological and translational implications. Nat Rev Cancer 11: 726-734
4. Berenbaum MC (1978) A method for testing for synergy with any number of agents. J Infect Dis 137: 122-130
5. Bian K, Fan J, Zhang X, Yang XW, Zhu HY, Wang L, Sun JY, Meng YL, Cui PC, Cheng SY et al (2012) MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal carcinoma cells by directly targeting survivin. FEBS Lett 586: 804-809
6. Bo J, Yang G, Huo K, Jiang H, Zhang L, Liu D, Huang Y (2011) microRNA-203 suppresses bladder cancer development by repressing bcl-w expression. FEBS J 278: 786-792
7. Borst P (2012) Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol. 2: 120066
8. Bovell LC, Shanmugam C, Putcha B-DK, Katkoori VR, Zhang B, Bae S, Singh KP, Grizzle WE, Manne U (2013) The prognostic value of micrornas varies with patient race/ethnicity and stage of colorectal cancer. Clin Cancer Res 19: 3955-3965
9. Brabletz T, Spaderna S, Kolb J, Hlubek F, Faller G, Bruns CJ, Jung A, Nentwich J, Duluc I, Domon-Dell C et al (2004) Down-regulation of the homeodomain factor Cdx2 in colorectal cancer by collagen type I: an active role for the tumor environment in malignant tumor progression. Cancer Res 64: 6973-6977
10. Brabletz S, Brabletz T (2010) The ZEB/miR-200 feedback loop-a motor of cellular plasticity in development and cancer? EMBO Rep 11: 670-677
11. Brabletz S, Bajdak K, Meidhof S, Burk U, Niedermann G, Firat E, Wellner U, Dimmler A, Faller G, Schubert J et al (2011) The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J 30: 770-782
12. Breitinger H-G (2012) Drug Synergy - Mechanisms and Methods of Analysis. In Toxicity and Drug Testing, Acree B (ed.), pp 143-166. Rijeka, Croatia: InTech
13. Buck E, Eyzaguirre A, Barr S, Thompson S, Sennello R, Young D, Iwata KK, Gibson NW, Cagnoni P, Haley JD (2007) Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther 6: 532-541
14. Chaffer Christine L, Marjanovic Nemanja D, Lee T, Bell G, Kleer Celina G, Reinhardt F, D'Alessio Ana C, Young Richard A, Weinberg Robert A (2013) Poised Chromatin at the ZEB1 Promoter Enables Breast Cancer Cell Plasticity and Enhances Tumorigenicity. Cell 154: 61-74
15. Clevers H (2011) The cancer stem cell: premises, promises and challenges. Nat Med 17: 313-319
16. Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW et al (2013) Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov 3: 1002-1019
17. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK (2009) MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 8: 1055-1066
18. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L et al (2011) Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 17: 500-503
19. Davalos V, Moutinho C, Villanueva A, Boque R, Silva P, Carneiro F, Esteller M (2011) Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 19: 2062-2074
20. Floor S, van Staveren WC, Larsimont D, Dumont JE, Maenhaut C (2011) Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations. Oncogene 30: 4609-4621
21. Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A, Liu J, Lu AH, Zhou NZ, Robert MF et al (2008) MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7: 759-768
22. Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon Y-J, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G et al (2012) EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 18: 74-82
23. Gheldof A, Hulpiau P, Roy F, Craene B, Berx G (2012) Evolutionary functional analysis and molecular regulation of the ZEB transcription factors. Cell Mol Life Sci 69: 2527-2541
24. Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P, Taubert H (2010) Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer 126: 73-80
25. He J, Deng Y, Yang G, Xie W (2013a) MicroRNA-203 down-regulation is associated with unfavorable prognosis in human glioma. J Surg Oncol 108: 121-125
26. He JH, Li YM, Li YG, Xie XY, Wang L, Chun SY, Cheng WJ (2013b) hsa-miR-203 enhances the sensitivity of leukemia cells to arsenic trioxide. Exp. Ther. Med. 5: 1315-1321
27. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13: 714-726
28. Huang PH, Chen CH, Chou CC, Sargeant AM, Kulp SK, Teng CM, Byrd JC, Chen CS (2011) Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases. Mol Pharmacol 79: 197-206
29. Ikenaga N, Ohuchida K, Mizumoto K, Yu J, Kayashima T, Sakai H, Fujita H, Nakata K, Tanaka M (2010) MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma. Ann Surg Oncol 17: 3120-3128
30. Krutzfeldt J, Kuwajima S, Braich R, Rajeev KG, Pena J, Tuschl T, Manoharan M, Stoffel M (2007) Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res 35: 2885-2892
31. Lena AM, Shalom-Feuerstein R, di Val Cervo PR, Aberdam D, Knight RA, Melino G, Candi E (2008) miR-203 represses/'stemness/' by repressing [Delta]Np63. Cell Death Differ 15: 1187-1195
32. Li Y, VandenBoom TG II, Kong D, Wang Z, Ali S, Philip PA, Sarkar FH (2009) Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69: 6704-6712
33. Li J, Chen Y, Zhao J, Kong F, Zhang Y (2011) miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression. Cancer Lett 304: 52-59
34. Lim Y-Y, Wright JA, Attema JL, Gregory PA, Bert AG, Smith E, Thomas D, Lopez AF, Drew PA, Khew-Goodall Y et al (2013) Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem-cell-like state. J Cell Sci 126: 2256-2266
35. Mongroo PS, Rustgi AK (2010) The role of the miR-200 family in epithelial-mesenchymal transition. Cancer Biol Ther 10: 219-222
36. Pena JT, Sohn-Lee C, Rouhanifard SH, Ludwig J, Hafner M, Mihailovic A, Lim C, Holoch D, Berninger P, Zavolan M et al (2009) miRNA in situ hybridization in formaldehyde and EDC-fixed tissues. Nat Methods 6: 139-141
37. Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265-273
38. Puhr M, Hoefer J, Schafer G, Erb HH, Oh SJ, Klocker H, Heidegger I, Neuwirt H, Culig Z (2012) Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol 181: 2188-2201
39. Puisieux A, Brabletz T, Caramel J (2014) Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol 16: 488-494
40. Ru P, Steele R, Hsueh EC, Ray RB (2011) Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity. Genes Cancer 2: 720-727
41. Saini S, Majid S, Yamamura S, Tabatabai L, Suh SO, Shahryari V, Chen Y, Deng G, Tanaka Y, Dahiya R (2011) Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis. Clin Cancer Res 17: 5287-5298
42. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E (2009) Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138: 592-603
43. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, Settleman J (2009) A gene expression signature associated with "K-Ras Addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 15: 489-500
44. Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751
45. Smith V, Wirth GJ, Fiebig HH, Burger AM (2008) Tissue microarrays of human tumor xenografts: characterization of proteins involved in migration and angiogenesis for applications in the development of targeted anticancer agents. Cancer Genomics Proteomics 5: 263-273
46. Spaderna S, Schmalhofer O, Wahlbuhl M, Dimmler A, Bauer K, Sultan A, Hlubek F, Jung A, Strand D, Eger A et al (2008) The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 68: 537-544
47. Sung V, Richard N, Brady H, Maier A, Kelter G, Heise C (2011) Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells. Cancer Sci 102: 1201-1207
48. Taube JH, Malouf GG, Lu E, Sphyris N, Vijay V, Ramachandran PP, Ueno KR, Gaur S, Nicoloso MS, Rossi S et al (2013) Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties. Sci Rep 3: 2687
49. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890
50. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E et al (2012) Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21: 430-446
51. Wang J, Scully K, Zhu X, Cai L, Zhang J, Prefontaine GG, Krones A, Ohgi KA, Zhu P, Garcia-Bassets I et al (2007) Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature 446: 882-887
52. Wang J, Lee S, Teh CE-Y, Bunting K, Ma L, Shannon MF (2009) The transcription repressor, ZEB1, cooperates with CtBP2 and HDAC1 to suppress IL-2 gene activation in T cells. Int Immunol 21: 227-235
53. Wang C, Zheng X, Shen C, Shi Y (2012) MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res 31: 58
54. Wei W, Wanjun L, Hui S, Dongyue C, Xinjun Y, Jisheng Z (2013) miR-203 inhibits proliferation of HCC cells by targeting survivin. Cell Biochem Funct 31: 82-85
55. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A et al (2009) The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 11: 1487-1495.
56. Wohrle S, Wallmen B, Hecht A (2007) Differential control of Wnt target genes involves epigenetic mechanisms and selective promoter occupancy by T-cell factors. Mol Cell Biol 27: 8164-8177
57. Yi R, Poy MN, Stoffel M, Fuchs E (2008) A skin microRNA promotes differentiation by repressing 'stemness'. Nature 452: 225-229
58. Zhang P, Sun Y, Ma L (2015) ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle 14: 481-487